683 related articles for article (PubMed ID: 31561568)
1. New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.
Cabello-Olmo M; Araña M; Radichev I; Smith P; Huarte E; Barajas M
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561568
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of type 1 diabetes.
Li L; Yi Z; Tisch R; Wang B
Arch Immunol Ther Exp (Warsz); 2008; 56(4):227-36. PubMed ID: 18726144
[TBL] [Abstract][Full Text] [Related]
3. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
Fändrich F; Ungefroren H
Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
[TBL] [Abstract][Full Text] [Related]
4. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes.
Pearson JA; Wong FS; Wen L
J Autoimmun; 2016 Jan; 66():76-88. PubMed ID: 26403950
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic basis of immunotherapies for type 1 diabetes mellitus.
Chen W; Xie A; Chan L
Transl Res; 2013 Apr; 161(4):217-29. PubMed ID: 23348026
[TBL] [Abstract][Full Text] [Related]
6. Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.
Kroger CJ; Clark M; Ke Q; Tisch RM
Front Immunol; 2018; 9():1891. PubMed ID: 30166987
[TBL] [Abstract][Full Text] [Related]
7. Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.
Maurice Morillon Y; Martin A; Gojanovich G; Wang B; Tisch R
Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):239-50. PubMed ID: 25790749
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
9. Combination Immunotherapy for Type 1 Diabetes.
Bone RN; Evans-Molina C
Curr Diab Rep; 2017 Jul; 17(7):50. PubMed ID: 28534310
[TBL] [Abstract][Full Text] [Related]
10. Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.
Christen U; Kimmel R
Front Endocrinol (Lausanne); 2020; 11():591083. PubMed ID: 33193102
[TBL] [Abstract][Full Text] [Related]
11. Increased plasmablasts enhance T cell-mediated beta cell destruction and promote the development of type 1 diabetes.
Ling Q; Shen L; Zhang W; Qu D; Wang H; Wang B; Liu Y; Lu J; Zhu D; Bi Y
Mol Med; 2022 Feb; 28(1):18. PubMed ID: 35123388
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in autoimmune type 1 diabetes.
Weigmann B; Franke RK; Daniel C
Rev Diabet Stud; 2012; 9(2-3):68-81. PubMed ID: 23403703
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy: Building a bridge to a cure for type 1 diabetes.
Bluestone JA; Buckner JH; Herold KC
Science; 2021 Jul; 373(6554):510-516. PubMed ID: 34326232
[TBL] [Abstract][Full Text] [Related]
14. T-lymphocyte recognition of beta cells in type 1 diabetes: clinical perspectives.
Boitard C
Diabetes Metab; 2013 Dec; 39(6):459-66. PubMed ID: 24139825
[TBL] [Abstract][Full Text] [Related]
15. The case for an autoimmune aetiology of type 1 diabetes.
Mannering SI; Pathiraja V; Kay TW
Clin Exp Immunol; 2016 Jan; 183(1):8-15. PubMed ID: 26313217
[TBL] [Abstract][Full Text] [Related]
16. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis.
Padgett LE; Broniowska KA; Hansen PA; Corbett JA; Tse HM
Ann N Y Acad Sci; 2013 Apr; 1281(1):16-35. PubMed ID: 23323860
[TBL] [Abstract][Full Text] [Related]
17. How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.
Vives-Pi M; Rodríguez-Fernández S; Pujol-Autonell I
Apoptosis; 2015 Mar; 20(3):263-72. PubMed ID: 25604067
[TBL] [Abstract][Full Text] [Related]
18. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.
Diaz-de-Durana Y; Lau J; Knee D; Filippi C; Londei M; McNamara P; Nasoff M; DiDonato M; Glynne R; Herman AE
PLoS One; 2013; 8(10):e78483. PubMed ID: 24205242
[TBL] [Abstract][Full Text] [Related]
19. Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity.
Kracht MJL; Zaldumbide A; Roep BO
Trends Endocrinol Metab; 2016 Jun; 27(6):353-362. PubMed ID: 27094501
[TBL] [Abstract][Full Text] [Related]
20. The immunology of type 1 diabetes.
Herold KC; Delong T; Perdigoto AL; Biru N; Brusko TM; Walker LSK
Nat Rev Immunol; 2024 Jun; 24(6):435-451. PubMed ID: 38308004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
